TGFB1 and non-small cell lung carcinoma: Other ISs were less commonly encountered in the TCGA NSCLC cohort, such as the C1 Wound healing (83 patients, 18.2%), C4 Lymphocyte depleted (20 patients, 4.4%), and C6 TGF-β dominant (28 patients, 6.1%) subtypes in the LUAD cohort; C2 IFN-γ dominant (181 patients, 37.7%), C3 Inflammatory (four patients, 0.8%), C4 Lymphocyte depleted (seven patients, 1.5%), and C6 TGF-β dominant (14 patients, 2.9%) subtypes in the LUSC cohort (24).